Navigation Links
FDA and NIH announce joint study on tobacco use and risk perceptions
Date:10/6/2011

The U.S. Food and Drug Administration and the National Institutes of Health today announced a joint, large-scale, national study of tobacco users to monitor and assess the behavioral and health impacts of new government tobacco regulations.

The initiative, called the Tobacco Control Act National Longitudinal Study of Tobacco Users, is the first large-scale NIH/FDA collaboration on tobacco regulatory research since Congress granted FDA the authority to regulate tobacco products in the Family Smoking Prevention and Tobacco Control Act of 2009.

Scientific experts at NIH's National Institute on Drug Abuse and the FDA's Center for Tobacco Products will coordinate the effort.

"The launch of this study signals a major milestone in addressing one of the most significant public health burdens of the 21st century," said FDA Commissioner Margaret A. Hamburg. "The results will strengthen FDA's ability to fulfill our mission to make tobacco-related death and disease part of America's past and will further guide us in targeting the most effective actions to decrease the huge toll of tobacco use on our nation's health."

Investigators will follow more than 40,000 users of tobacco-product and those at risk for tobacco use ages 12 and older. They will examine what makes people susceptible to tobacco use; evaluate use patterns and resulting health problems; study patterns of tobacco cessation and relapse in the era of tobacco regulation; evaluate the effects of regulatory changes on risk perceptions and other tobacco-related attitudes; and assess differences in attitudes, behaviors and key health outcomes in racial-ethnic, gender, and age subgroups.

"We are pleased to collaborate with the FDA on this study that may provide us with a better understanding of the impact of product regulation on tobacco prevention and cessation," said NIH Director Francis S. Collins, M.D., Ph.D.

Westat, in Rockville, Md., was awarded the research contract in a competitive solicitation process. Study findings will help the FDA assess the impact of the Tobacco Control Act and will inform the agency about how to best use its tobacco regulatory authorities, such as making decisions about marketing of products, setting product standards, and communicating the risks from tobacco use to protect the public health.

While smoking rates have dropped significantly since their peak in the 1960s, nearly 70 million Americans ages 12 and older were current users of tobacco products in 2010. As a result, death and disease caused by tobacco use is still a tremendous public health burden. Tobacco use is the leading preventable cause of disease, disability, and death in the United States. Cigarette smoking results in more than 443,000 premature deaths in the United States each year more than alcohol, illegal drug use, homicide, suicide, car accidents, and AIDS combined.


'/>"/>

Contact: NIDA Press Office
media@nida.nih.gov
301-443-6245
NIH/National Institute on Drug Abuse
Source:Eurekalert

Related medicine news :

1. Company stock prices before public announcements of oncology trial results
2. NIDA Avant-Garde-Medications Development Award winners announced
3. IDSA/PIDS announce guidelines for treating pneumonia in children
4. URMC and Temple announce drug discovery partnership
5. ESC announces review of Atrial Fibrillation Guidelines
6. The Waxman Foundation announces $25,000 grant in B-cell lymphoma research
7. INFORMS journal announces special issue on using logistics, analytics in humanitarian relief
8. Joint winners announced in Research4life global case study competition
9. ASTRO announces 2011 Fellows class
10. Leading research organizations announce top-tier journal for biomedical and life sciences
11. Massachusetts General Hospital, Iacocca Foundation announce promising results of Phase I diabetes trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... “Some Infallible Characteristics of Christ”: a fascinating and ... Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, the third ... a preacher for over nineteen, a pastor for over fifteen years. He is a ...
(Date:1/22/2017)... TX (PRWEB) , ... January 22, 2017 , ... ... provide slow results. Often the results of a simple test will take days to ... Any Lab Test Now offers customers direct access to their lab tests, bypassing the ...
(Date:1/21/2017)... ... ... Phytocéane invites you to take an exotic journey deep into ... ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a Tanzanian archipelago off the ... coral to create this gentle, crystal-clear shower gel to cleanse the body and promote ...
(Date:1/21/2017)... ... January 21, 2017 , ... The Nobel Biocare™ dental ... in media for its creos™ line of bone regenerative products. Specifically, the ... which he utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction ...
(Date:1/20/2017)... ... 20, 2017 , ... Doctor C LLC, a company based out of Arizona ... to continue the marketing and distribution of its product, The Right C. , The ... better absorption than traditional vitamin C supplements. At the trade show, Doctor C had ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is ... incidence of depression worldwide is anticipated to drive the market growth in the ... demand for antidepressants in the recent years. Continue ... ... ...
(Date:1/23/2017)... 23 janvier 2017  ResMed (NYSE : RMD), BMC (Pékin, ... ont annoncé aujourd,hui qu,ils se sont mis d,accord sur ... les parties. BMC et 3B seront autorisés à vendre ... à ResMed, et ResMed effectuera le paiement de la ... le litige de Floride entre les deux parties. Le ...
(Date:1/23/2017)... DIEGO , 23. Januar 2017  ResMed (NYSE: ... ) und 3B Medical ( Winter Haven, ... auf eine Vereinbarung über die Beilegung aller globalen Rechtsstreitigkeiten ... der Verkauf ihrer bestehenden Produkte im Tausch ... einmalige Zahlung an 3B leisten, um das in ...
Breaking Medicine Technology: